Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · CellCept
CellCept 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-085164 · Präparat HOS-083095
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 38a6790d989fb2086bcd78166cdb9ac1029b47140afbab4f00aac9bf32a351b5 · Zeichen 698–1373 im Abschnitt
Wechselwirkungen · CellCept
CellCept 1 g/5 ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 49
HOS-085320 · Präparat HOS-083095
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 38a6790d989fb2086bcd78166cdb9ac1029b47140afbab4f00aac9bf32a351b5 · Zeichen 698–1373 im Abschnitt
Wechselwirkungen · CellCept
CellCept 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 72
HOS-085392 · Präparat HOS-083095
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 38a6790d989fb2086bcd78166cdb9ac1029b47140afbab4f00aac9bf32a351b5 · Zeichen 698–1373 im Abschnitt
Wechselwirkungen · Plavix
Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-087950 · Präparat HOS-083591
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-14T12:15:00Z · SHA-256 1e6a9d1e2861882ccf51f6506686a24b3c88e112fad66a7a9333c6e88547592c · Passage 8741959ca26ef1991d9f10cb8dc0408f0677a8d230580e185084c52e76eb6108 · Zeichen 5236–5713 im Abschnitt
Wechselwirkungen · Iscover
Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-088001 · Präparat HOS-083599
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-26T11:41:00Z · SHA-256 3fe5799ec5f9f1d2b848168c6cfaf56d702c6bce3141e7d7aa95ef81abbc8acc · Passage 8741959ca26ef1991d9f10cb8dc0408f0677a8d230580e185084c52e76eb6108 · Zeichen 5235–5712 im Abschnitt
Wechselwirkungen · Procoralan
Procoralan 5 mg film-coated tablets Procoralan 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113863 · Präparat HOS-093985
Other concomitant use
Specific interaction studies have shown no clinically significant effect of the following medicinal
products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors
(omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine
calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no
7
clinically significant effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine,
lacidipine, on the pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the
pharmacodynamics of aspirin.
In pivotal phase III clinical trials the following medicinal products were routinely combined with
ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin
II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG
CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-
platelet medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) aspirin (HOS-111273) lacidipine (HOS-113865) aldosterone (HOS-086926) amlodipine (HOS-086287) simvastatin (HOS-086158) digoxin (HOS-086172) calcium (HOS-085615) sildenafil (HOS-086162) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:49:00Z · SHA-256 603a04f5264f2cd02119b9fdddd8869a5b599fbe491c4482b048613e56f12c88 · Passage 6fe50dfb92b6505d72aae832687fd6d506058eea7817db26b92c97470c5cf7b0 · Zeichen 3733–4843 im Abschnitt
Wechselwirkungen · Corlentor
Corlentor 5 mg film-coated tablets Corlentor 7.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-113899 · Präparat HOS-093993
Other concomitant use
Specific interaction studies have shown no clinically significant effect of the following medicinal
products on pharmacokinetics and pharmacodynamics of ivabradine: proton pump inhibitors
(omeprazole, lansoprazole), sildenafil, HMG CoA reductase inhibitors (simvastatin), dihydropyridine
7
calcium channel blockers (amlodipine, lacidipine), digoxin and warfarin. In addition there was no
clinically significant effect of ivabradine on the pharmacokinetics of simvastatin, amlodipine,
lacidipine, on the pharmacokinetics and pharmacodynamics of digoxin, warfarin and on the
pharmacodynamics of aspirin.
In pivotal phase III clinical trials the following medicinal products were routinely combined with
ivabradine with no evidence of safety concerns: angiotensin converting enzyme inhibitors, angiotensin
II antagonists, beta-blockers, diuretics, anti-aldosterone agents, short and long acting nitrates, HMG
CoA reductase inhibitors, fibrates, proton pump inhibitors, oral antidiabetics, aspirin and other anti-
platelet medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) aspirin (HOS-111273) lacidipine (HOS-113865) aldosterone (HOS-086926) amlodipine (HOS-086287) simvastatin (HOS-086158) digoxin (HOS-086172) calcium (HOS-085615) sildenafil (HOS-086162) warfarin (HOS-085950) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-17T17:03:00Z · SHA-256 d87e68351dedcde32d83ee33c2f0d9205f341c44bb5b4d122f4a04ffba50a0e0 · Passage fa836be3022093cccc5a3b6212d038585510c2a7d953cbad3447bdbe000be9a4 · Zeichen 3735–4845 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 19
HOS-114841 · Präparat HOS-094169
Antacids
aluminium- and Tipranavir Cmax ↓ 25% Dosing of Aptivus, co-
magnesium-based antacid Tipranavir AUC ↓ 27% administered with low dose
QD ritonavir, with antacids should be
Mechanism unknown separated by at least a two hours
time interval.
Proton pump inhibitors (PPIs)
Omeprazole 40 mg QD Omeprazole Cmax ↓ 73% The combined use of Aptivus, co-
Omeprazole AUC ↓ 70% administered with low dose
ritonavir, with either omeprazole
Similar effects were observed for or esomeprazole is not
the S-enantiomer, esomeprazole. recommended (see section 4.4). If
unavoidable, upward dose
Induction of CYP 2C19 by adjustments for either
tipranavir/r omeprazole or esomeprazole may
be considered based on clinical
Tipranavir ↔ response to therapy. There are no
data available indicating that
omeprazole or esomeprazole dose
adjustments will overcome the
observed pharmacokinetic
interaction. Recommendations
for maximal doses of omeprazole
or esomeprazole are found in the
corresponding product
information. No tipranavir with
ritonavir dose adjustment is
required.
Lansoprazole Based on the metabolic profiles The combined use of Aptivus, co-
Pantoprazole of tipranavir/r and the proton administered with low dose
Rabeprazole pump inhibitors, an interaction ritonavir, with proton pump
No interaction study can be expected. As a result of inhibitors is not recommended
performed CYP3A4 inhibition and (see section 4.4). If the co-
CYP2C19 induction by administration is judged
tipranavir/r, lansoprazole and unavoidable, this should be done
pantoprazole plasma under close clinical monitoring.
concentrations are difficult to
predict. Rabeprazole plasma
concentrations might decrease as
a result of induction of CYP2C19
by tipranavir/r.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) rabeprazole (HOS-114843) esomeprazole (HOS-087944) pantoprazole (HOS-085167) ritonavir (HOS-084521) omeprazole (HOS-085912)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage c99aa431c7e3f77cb519d4da2aced0a374d801c9c352b5d32534ed58e4e72798 · Zeichen 45182–48575 im Abschnitt
Wechselwirkungen · Advagraf
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules · Abschnitt 4.5 · PDF-Seite 10–11
HOS-116802 · Präparat HOS-094481
10
Drug/Substance Class or Drug interaction effect Recommendations concerning
Name co-administration
Strong CYP3A4 inhibitors: May increase tacrolimus whole It is recommended that
antifungal agents (e.g., blood trough concentrations and concomitant use should be
ketoconazole, itraconazole, increase the risk of serious adverse avoided. If co-administration
posaconazole, voriconazole), reactions (e.g., nephrotoxicity, of a strong CYP3A4 inhibitor
the macrolide antibiotics neurotoxicity, QT prolongation) is unavoidable, consider
(e.g., telithromycin, which requires close monitoring omitting the dose of tacrolimus
troleandomycin, [see section 4.4]. the day the strong CYP3A4
clarithromycin, josamycin), Rapid and sharp increases in inhibitor is initiated. Reinitiate
HIV protease inhibitors tacrolimus levels may occur, as tacrolimus the next day at a
(e.g., ritonavir, nelfinavir, early as within 1-3 days after co- reduced dose based on
saquinavir), HCV protease administration, despite immediate tacrolimus blood
inhibitors (e.g., telaprevir, reduction of tacrolimus dose. concentrations. Changes in
boceprevir, and the Overall tacrolimus exposure may both tacrolimus dose and/or
combination of ombitasvir increase > 5 fold. When ritonavir dosing frequency should be
and paritaprevir with combinations are co-administered, individualized and adjusted as
ritonavir, when used with tacrolimus exposure may increase needed based on tacrolimus
and without dasabuvir), > 50 fold. Nearly all patients may trough concentrations, which
nefazodone, the require a reduction in tacrolimus should be assessed at initiation,
pharmacokinetic enhancer dose and temporary interruption of monitored frequently
cobicistat, and the kinase tacrolimus may also be necessary. throughout (starting within the
inhibitors idelalisib, The effect on tacrolimus blood first few days) and re-
ceritinib. concentrations may remain for evaluated on and after
Strong interactions have also several days after co-administration completion of the CYP3A4
been observed with the is completed. inhibitor. Upon completion,
macrolide antibiotic appropriate dose and dosing
erythromycin frequency of tacrolimus should
be guided by tacrolimus blood
concentrations. Monitor renal
function, ECG for QT
prolongation, and other side
effects closely.
Moderate or weak CYP3A4 May increase tacrolimus whole Monitor tacrolimus whole
inhibitors: blood trough concentrations and blood trough concentrations
antifungal agents (e.g., increase the risk of serious adverse frequently, starting within the
fluconazole, isavuconazole, reactions (e.g., neurotoxicity, QT first few days of co-
clotrimazole, miconazole), prolongation) [see section 4.4]. A administration. Reduce
the macrolide antibiotics rapid increase in tacrolimus level tacrolimus dose if needed [see
(e.g., azithromycin), calcium may occur. section 4.2]. Monitor renal
channel blockers (e.g., function, ECG for QT
nifedipine, nicardipine, prolongation, and other side
diltiazem, verapamil), effects closely.
amiodarone, danazol,
ethinylestradiol,
lansoprazole, omeprazole,
the HCV antivirals
elbasvir/grazoprevir and
glecaprevir/pibrentasvir, the
CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib,
crizotinib and imatinib and
(Chinese) herbal remedies
containing extracts of
Schisandra sphenanthera
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) ceritinib (HOS-086215) josamycin (HOS-113844) diltiazem (HOS-086288) nefazodone (HOS-084519) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) nelfinavir (HOS-084520) nicardipine (HOS-090619) protease (HOS-085623) ketoconazole (HOS-084513) pibrentasvir (HOS-086298) crizotinib (HOS-116818) cobicistat (HOS-088111) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) calcium (HOS-085615) imatinib (HOS-110212) dasabuvir (HOS-110302) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) grazoprevir (HOS-108815) itraconazole (HOS-084516) saquinavir (HOS-084522) danazol (HOS-085473) fluconazole (HOS-087945) ombitasvir (HOS-110300) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) troleandomycin (HOS-090575) ritonavir (HOS-084521) amiodarone (HOS-085596) paritaprevir (HOS-110301) tyrosine (HOS-108875) posaconazole (HOS-085622) nilotinib (HOS-086218) miconazole (HOS-115630) idelalisib (HOS-116811) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-02-27T10:10:00Z · SHA-256 0ed42bc08ffe6bd7e6c8ed94445bdb8b8c9971dabe41ef3a899ec75fc2f97c0e · Passage 871fa2c72a31ddd6873cbb2f1b3b0dd9ad898b46eba141ac32a052a178cc3bc9 · Zeichen 3910–8415 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-209308 · Präparat HOS-154301
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage 10ca881923c206495674af7dad34b2a8a60a51c81ce5bb893943688a7d8be7e9 · Zeichen 698–1374 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-209387 · Präparat HOS-154301
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co-administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage 38a6790d989fb2086bcd78166cdb9ac1029b47140afbab4f00aac9bf32a351b5 · Zeichen 698–1373 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-209458 · Präparat HOS-154315
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage 10ca881923c206495674af7dad34b2a8a60a51c81ce5bb893943688a7d8be7e9 · Zeichen 698–1374 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-209526 · Präparat HOS-154315
Decreased MPA exposure has been observed when antacids, such as magnesium and aluminium
hydroxides, and PPIs, including lansoprazole and pantoprazole, were administered with
mycophenolate mofetil. When comparing rates of transplant rejection or rates of graft loss between
mycophenolate mofetil patients taking PPIs vs. mycophenolate mofetil patients not taking PPIs, no
significant differences were seen. These data support extrapolation of this finding to all antacids
because the reduction in exposure when mycophenolate mofetil was co- administered with magnesium
and aluminium hydroxides is considerably less than when mycophenolate mofetil was co-administered
with PPIs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) magnesium (HOS-085165)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage 10ca881923c206495674af7dad34b2a8a60a51c81ce5bb893943688a7d8be7e9 · Zeichen 698–1374 im Abschnitt
Wechselwirkungen · Modigraf
Modigraf 0.2 mg granules for oral suspension Modigraf 1 mg granules for oral suspension · Abschnitt 4.5 · PDF-Seite 11–12
HOS-209751 · Präparat HOS-154375
11
Drug/Substance Class or Drug interaction effect Recommendations concerning co-
Name administration
The effect on tacrolimus
blood concentrations may
remain for several days after
co-administration is
completed.
Moderate or weak CYP3A4 May increase tacrolimus Monitor tacrolimus whole blood
inhibitors: whole blood trough trough concentrations frequently,
antifungal agents (e.g., concentrations and increase starting within the first few days
fluconazole, isavuconazole, the risk of serious adverse of co-administration. Reduce
clotrimazole, miconazole), reactions (e.g., neurotoxicity, tacrolimus dose if needed [see
the macrolide antibiotics QT prolongation) [see section 4.2]. Monitor renal
(e.g., azithromycin), calcium section 4.4]. A rapid increase function, ECG for QT
channel blockers (e.g., in tacrolimus level may prolongation, and other side
nifedipine, nicardipine, occur. effects closely.
diltiazem, verapamil),
amiodarone, danazol,
ethinylestradiol, lansoprazole,
omeprazole, the HCV
antivirals elbasvir/grazoprevir
and glecaprevir/pibrentasvir,
the CMV antiviral letermovir,
and the tyrosine kinase
inhibitors nilotinib, crizotinib
and imatinib and (Chinese)
herbal remedies containing
extracts of Schisandra
sphenanthera
In vitro the following May increase tacrolimus Monitor tacrolimus whole blood
substances have been shown whole blood trough trough concentrations and reduce
to be potential inhibitors of concentrations and increase tacrolimus dose if needed [see
tacrolimus metabolism: the risk of serious adverse section 4.2].
bromocriptine, cortisone, reactions (e.g., neurotoxicity, Monitor renal function, ECG for
dapsone, ergotamine, QT prolongation) [see QT prolongation, and other side
gestodene, lidocaine, section 4.4]. effects closely.
mephenytoin, midazolam,
nilvadipine, norethisterone,
quinidine, tamoxifen
Strong CYP3A4 inducers: May decrease tacrolimus It is recommended that
rifampicin, phenytoin whole blood trough concomitant use should be
carbamazepine, apalutamide, concentrations and increase avoided. If unavoidable, patients
enzalutamide, mitotane or St. the risk of rejection [see may require an increase in
John’s wort (Hypericum section 4.4]. tacrolimus dose. Changes in
perforatum) Maximal effect on tacrolimus tacrolimus dose should be
blood concentrations may be individualized and adjusted as
achieved 1-2 weeks after co- needed based on tacrolimus
administration. The effect trough concentrations, which
may remain 1-2 weeks after should be assessed at initiation,
completion of the treatment. monitored frequently throughout
(starting within the first few days)
and re-evaluated on and after
completion of the CYP3A4
inducer. After use of the CYP3A4
inducer has ended, tacrolimus
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) letermovir (HOS-090621) diltiazem (HOS-086288) elbasvir (HOS-108814) isavuconazole (HOS-085186) nifedipine (HOS-086289) cortisone (HOS-114161) nicardipine (HOS-090619) pibrentasvir (HOS-086298) lidocaine (HOS-108866) carbamazepine (HOS-085618) crizotinib (HOS-116818) apalutamide (HOS-086212) tamoxifen (HOS-088380) quinidine (HOS-085593) glecaprevir (HOS-086297) azithromycin (HOS-088112) clotrimazole (HOS-090574) mephenytoin (HOS-109801) calcium (HOS-085615) imatinib (HOS-110212) grazoprevir (HOS-108815) danazol (HOS-085473) mitotane (HOS-112479) fluconazole (HOS-087945) bromocriptine (HOS-090620) nilvadipine (HOS-116826) gestodene (HOS-116824) ergotamine (HOS-086154) amiodarone (HOS-085596) tyrosine (HOS-108875) dapsone (HOS-088141) phenytoin (HOS-084531) enzalutamide (HOS-116829) nilotinib (HOS-086218) miconazole (HOS-115630) midazolam (HOS-086167) omeprazole (HOS-085912) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-03T17:00:00Z · SHA-256 1a464ac051c5783e49ce08a9d103d0d319997aa4add60584450928c1b11144a7 · Passage 1e7cc303a6d0d182851c23281c6a79a17f96d714a9cddc0ab3d6ada78ab947ab · Zeichen 6985–10993 im Abschnitt
Wechselwirkungen · Clopidogrel Zentiva (previously Clopidogrel Winthrop)
Clopidogrel Zentiva 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-209894 · Präparat HOS-154399
7
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-03T16:45:00Z · SHA-256 e0215a720388221c98b7ac2dbc71d7bb651807eaa839c43dbd3c29e450499ab6 · Passage 4ed9cb34dbbb1c5e71ace2889f4d343a74408c07219f1bb26e80a17ad406c5d8 · Zeichen 5217–5697 im Abschnitt
Wechselwirkungen · Efient
Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-120774 · Präparat HOS-095209
Medicinal products that elevate gastric pH:
Daily co-administration of ranitidine (an H2 blocker) or lansoprazole (a proton pump inhibitor) did not
change the prasugrel active metabolite’s AUC and Tmax, but decreased the Cmax by 14% and 29%,
respectively. In the phase 3 clinical trial, Efient was administered without regard to co-administration
of a proton pump inhibitor or H2 blocker. Administration of the 60 mg prasugrel loading dose without
concomitant use of proton pump inhibitors may provide most rapid onset of action.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) ranitidine (HOS-085660)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-22T14:15:00Z · SHA-256 bf0eaa99dea4480cd15ea241fb41ce985dc8e97851472df117f97dc0c795a95e · Passage f890338de42acf8500753110f843f50cd7e44ada27cfa068ebbecbcecc32525d · Zeichen 2418–2947 im Abschnitt
Wechselwirkungen · Clopidogrel Teva (hydrogen sulphate)
Clopidogrel Teva 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-210576 · Präparat HOS-154547
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T12:25:00Z · SHA-256 2668df6ec61f9f4f66d3079105d2dc6c533c7c482102d41117d3a9ecab3c3583 · Passage 8741959ca26ef1991d9f10cb8dc0408f0677a8d230580e185084c52e76eb6108 · Zeichen 5231–5708 im Abschnitt
Wechselwirkungen · Clopidogrel Krka
Clopidogrel Krka 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-210636 · Präparat HOS-154555
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-14T09:49:00Z · SHA-256 de285f540dd9461c605738f58c4125215a83fbcefb35a3be3d9119eb1b2b68a9 · Passage 8741959ca26ef1991d9f10cb8dc0408f0677a8d230580e185084c52e76eb6108 · Zeichen 5175–5652 im Abschnitt
Wechselwirkungen · Zyllt
Zyllt 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-121548 · Präparat HOS-095389
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) during concomitant treatment with pantoprazole 80 mg once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that clopidogrel can be administered with pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167) clopidogrel (HOS-087927)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-14T12:07:00Z · SHA-256 f7bf5ef29f88fd676dd0507812419bb944fe4584c2c7bb6fde3ba14cc8084d6f · Passage 8741959ca26ef1991d9f10cb8dc0408f0677a8d230580e185084c52e76eb6108 · Zeichen 5175–5652 im Abschnitt
Wechselwirkungen · Grepid
Grepid 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-121589 · Präparat HOS-095397
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or
lansoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lansoprazole (HOS-085166) pantoprazole (HOS-085167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-23T11:55:00Z · SHA-256 77bedbd07ba7109037505e509b70d3e89cce68a41661a537751991f1f383eb00 · Passage 9b3bc1d324571e9c694a8f903e2b2c6251031857d6526397a695aa6404be01d9 · Zeichen 5180–5282 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.